Opioid-induced biochemical alterations of the neuroendocrine axis

References

• Kapoor LD. Opium Poppy: Botany, Chemistry and Pharmacology. Food Products Press, NY, USA (1995).
   Google Scholar
• Booth M. Opium: A History. St Martin’s Press, NY, USA (1998).
   Google Scholar
• Bruce C. Report on the manufacture of tea, and on the extent and produce of the tea plantations in Assam. As. Soc. Bengal J.8, 497–526 (1839).
   Google Scholar
• Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu. Rev. Biochem.73, 953–990 (2004).
   PubMed Web of Science ®Google Scholar
• Chiou LC, Fan SH, Chuang KC, Liao YY, Lee SZ. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray. Ann. NY Acad. Sci.1025, 398–403 (2004).
   PubMed Web of Science ®Google Scholar
• Koneru A. Endogenous opioids: their physiologic roles and receptors. Global J. Pharmacol.3(3), 149–153 (2009).
   Google Scholar
• Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr. Rev.31(1), 98–132 (2010).
   PubMed Web of Science ®Google Scholar
• Grossman A. Brain opiates and neuroendocrine function. Clin. Endocrinol. Metab.12(3), 725–746 (1983).
   PubMedGoogle Scholar
• Browning Af BW, London DR. The interaction of female sex steroids and endogenous opioids on the inhibition of pituitary gonadotrophin release. Acta Endocrinol.97(Suppl. 243), (1981) (Abstract 191).
   Google Scholar
• Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin. J. Pain26(5), 374–380 (2010).
   PubMed Web of Science ®Google Scholar
• Allolio B, Schulte HM, Deuss U, Kallabis D, Hamel E, Winkelman W. Effect of oral morphine and naloxone on pituitary–adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol.114(4), 509–514 (1987).
   PubMedGoogle Scholar
• Schluger JH, Bart G, Green M, Ho A, Kreek MJ. Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained vs control subjects. Neuropsychopharmacology28(5), 985–994 (2003).
   PubMed Web of Science ®Google Scholar
• Bronstein DM, Gutstein HB, Akil H. Effects of chronic morphine treatment on β-endorphin-related peptides in the caudal medulla and spinal cord. J. Neurochem.60(6), 2304–2307 (1993).
   PubMedGoogle Scholar
• Heybach JP, Vernikos J. Naloxone inhibits and morphine potentiates the adrenal steroidogenic response to ACTH. Eur. J. Pharmacol.75(1), 1–6 (1981).
   PubMedGoogle Scholar
• Facchinetti F, Grasso A, Petraglia F, Parrini D, Volpe A, Genazzani AR. Impaired circadian rhythmicity of β-lipotrophin, β-endorphin and ACTH in heroin addicts. Acta Endocrinol.105(2), 149–155 (1984).
   PubMedGoogle Scholar
• Abs R, Verhelst J, Maeyaert J et al. Endocrine consequences of long-term intrathecal administration of opioids. J. Clin. Endocrinol.Metab.85(6), 2215–2222 (2000).
   PubMed Web of Science ®Google Scholar
• Oltmanns KM, Fehm HL, Peters A. Chronic fentanyl application induces adrenocortical insufficiency. J. Intern. Med.257(5), 478–480 (2005).
   PubMed Web of Science ®Google Scholar
• Aloisi AM, Aurilio C, Bachiocco V et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology34(Suppl. 1), S162–S168 (2009).
   Google Scholar
• Roche DJ, Childs E, Epstein AM, King AC. Acute HPA axis response to naltrexone differs in female vs. male smokers. Psychoneuroendocrinology35(4), 596–606 (2010).
   PubMedGoogle Scholar
• Grossman A, Moult PJ, Mcintyre H et al. Opiate mediation of amenorrhoea in hyperprolactinaemia and in weight-loss related amenorrhoea. Clin. Endocrinol.17(4), 379–388 (1982).
   PubMed Web of Science ®Google Scholar
• Lafisca S, Bolelli G, Franceschetti F, Filicori M, Flamigni C, Marigo M. Hormone levels in methadone-treated drug addicts. Drug Alcohol Depend.8(3), 229–234 (1981).
   PubMed Web of Science ®Google Scholar
• Merza Z. Chronic use of opioids and the endocrine system. Horm. Metab. Res.42(9), 621–626 (2010).
   PubMed Web of Science ®Google Scholar
• Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin. J. Pain25(2), 170–175 (2009).
   PubMed Web of Science ®Google Scholar
• Ceccarelli I, De Padova AM, Fiorenzani P, Massafra C, Aloisi AM. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience140(3), 929–937 (2006).
   PubMed Web of Science ®Google Scholar
• Celani MF, Carani C, Montanini V et al. Further studies on the effects of heroin addiction on the hypothalamic–pituitary–gonadal function in man. Pharmacol. Res. Commun.16(12), 1193–1203 (1984).
   PubMedGoogle Scholar
• Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer100(4), 851–858 (2004).
   PubMedGoogle Scholar
• Fraser LA, Morrison D, Morley-Forster P et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp. Clin. Endocrinol. Diabetes117(1), 38–43 (2009).
   PubMed Web of Science ®Google Scholar
• Petraglia F, Porro C, Facchinetti F et al. Opioid control of LH secretion in humans: menstrual cycle, menopause and aging reduce effect of naloxone but not of morphine. Life Sci.38(23), 2103–2110 (1986).
   PubMed Web of Science ®Google Scholar
• Reid RL, Quigley ME, Yen SS. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women. J. Clin. Endocrinol. Metab.57(6), 1107–1110 (1983).
   PubMed Web of Science ®Google Scholar
• Colameco S, Coren JS. Opioid-induced endocrinopathy. J. Am. Osteopath. Assoc.109(1), 20–25 (2009).
   PubMedGoogle Scholar
• Pelosi MA, Sama JC, Caterini H, Kaminetzky HA. Galactorrhea-amenorrhea syndrome associated with heroin addiction. Am. J. Obstet. Gynecol.118(7), 966–970 (1974).
   PubMedGoogle Scholar
• Woody GMA, O’Brein C et al. Hormone secretion in methadone dependent and abstinent patients. NIDA Res. Monograph.81, 216–223 (1998).
   Google Scholar
• Lindow SW, Hendricks MS, Nugent FA, Dunne TT, Van Der Spuy ZM. Morphine suppresses the oxytocin response in breast-feeding women. Gynecol. Obstet. Invest.48(1), 33–37 (1999).
   PubMedGoogle Scholar
• Steardo L, Monteleone P, Tamminga CA et al. Differential responses in prolactin levels induced by naloxone in humans. Psychoneuroendocrinology10(2), 203–209 (1985).
   PubMedGoogle Scholar
• Vescovi PP, Pezzarossa A, Ceresini G, Rastelli G, Valenti G, Gerra G. Effects of dopamine receptor stimulation on opiate-induced modifications of pituitary-gonadal function. Horm. Res.21(3), 155–159 (1985).
   PubMedGoogle Scholar
• Borer KT, Nicoski DR, Owens V. Alteration of pulsatile growth hormone secretion by growth-inducing exercise: involvement of endogenous opiates and somatostatin. Endocrinology118(2), 844–850 (1986).
   PubMedGoogle Scholar
• Barbarino A, De Marinis L, Mancini A et al. Sex-related naloxone influence on growth hormone-releasing hormone-induced growth hormone secretion in normal subjects. Metabolism36(2), 105–109 (1987).
   PubMed Web of Science ®Google Scholar
• Demarinis LMA, Valle D et al. Influence of chronic naltrexone treatment on growth hormone and insulin secretion in obese subjects. Int. J. Obes. Relat. Metab. Disord.21, 1076–1081 (1997).
   PubMedGoogle Scholar
• Villa P, Valle D, Mancini A et al. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism. Fertil. Steril.71(1), 115–121 (1999).
   PubMedGoogle Scholar
• Michel C, Montastruc JL, Valdiguie P, Montastruc P. Effects of morphine on urine flow in rats. Involvement of vasopressin. J. Pharmacol.17(3), 316–322 (1986).
   PubMedGoogle Scholar
• Iremonger KJ, Bains JS. Retrograde opioid signaling regulates glutamatergic transmission in the hypothalamus. J. Neurosci.29(22), 7349–7358 (2009).
   PubMedGoogle Scholar
• Rossi NF, Kim JK, Summers SN, Schrier RW. κ opiate agonist RU 51599 inhibits vasopressin gene expression and osmotically-induced vasopressin secretion in vitro. Life Sci.61(23), 2271–2282 (1997).
   PubMedGoogle Scholar
• Tsushima H, Mori M, Matsuda T. Central regulation of urine production by a selective µ-opioid agonist, [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin, in rats. Jpn. J. Pharmacol.74(1), 45–49 (1997).
   PubMedGoogle Scholar
• Sarret D, Le Berre JP, Zemraoui N. Tramadol-induced hyponatremia. Am. J. Kidney Dis.52(5), 1026; author reply 1027 (2008).
   PubMedGoogle Scholar
• Bozkurt P, Kaya G, Yeker Y et al. Effects of systemic and epidural morphine on antidiuretic hormone levels in children. Paediatr. Anaesth.13(6), 508–514 (2003).
   PubMedGoogle Scholar
• Grossman A, Besser GM, Milles JJ, Baylis PH. Inhibition of vasopressin release in man by an opiate peptide. Lancet2(8204), 1108–1110 (1980).
   PubMedGoogle Scholar
• Lindow SW, Van Der Spuy ZM, Hendricks MS, Nugent FA, Dunne TT. The effect of morphine and naloxone administration on maternal oxytocin concentration in late pregnancy. Clin. Endocrinol.39(6), 671–675 (1993).
   PubMedGoogle Scholar
• George S. Review of neuroendocrine correlates of chronic opiate misuse: dysfunctions and pathophysiological mechanisms. Addict. Disord. Treat.4(3), 99–109 (2005).
   Google Scholar
• Azizi F, Vagenakis AG, Portnay GI, Braverman LE, Ingbar SH. Thyroxine transport and metabolism in methadone and heroin addicts. Ann. Intern. Med.80(2), 194–199 (1974).
   PubMed Web of Science ®Google Scholar
• English TN, Ruxton D, Eastman CJ. Abnormalities in thyroid function associated with chronic therapy with methadone. Clin. Chem.34(11), 2202–2204 (1988).
   PubMedGoogle Scholar
• Chan V, Wang C, Yeung RT. Effects of heroin addiction on thyrotrophin, thyroid hormones and porlactin secretion in men. Clin. Endocrinol. (Oxf.)10(6), 557–565 (1979).
   PubMedGoogle Scholar
• Pende A, Musso NR, Montaldi ML, Pastorino G, Arzese M, Devilla L. Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. Biomed. Pharmacother.40(5), 178–182 (1986).
   PubMedGoogle Scholar
• Shenkman L, Massie B, Mitsuma T, Hollander CS. Effects of chronic methadone administration on the hypothalamic–pituitary–thyroid axis. J. Clin. Endocrinol. Metab.35(1), 169–170 (1972).
   PubMedGoogle Scholar
• Brambilla F, Guerrini A, Guastalla A, Beretta P, Maio DD. Glucose-insulin metabolism in herion addicts. Neuropsychobiology2(5–6), 341–349 (1976).
   PubMedGoogle Scholar
• Ghodse AH. Evaluation of blood glucose, insulin, growth hormone and cortisol response in heroin addicts. Pahlavi Med. J.8(2), 141–156 (1977).
   PubMedGoogle Scholar
• Sadava D, Alonso D, Hong H, Pettit-Barrett DP. Effect of methadone addiction on glucose metabolism in rats. Gen. Pharmacol.28(1), 27–29 (1997).
   PubMedGoogle Scholar
• Grey A, Rix-Trott K, Horne A, Gamble G, Bolland M, Reid IR. Decreased bone density in men on methadone maintenance therapy. Addiction106(2), 349–354 (2011).
   PubMed Web of Science ®Google Scholar
• Perez-Castrillon JL, Olmos JM, Gomez JJ et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology72(3), 187–194 (2000).
   PubMed Web of Science ®Google Scholar
• Canalis E. Regulation of bone remodeling. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Favus MJ (Ed.) American Society for Bone and Mineral Research, Washington, DC, USA, 23–26 (1990).
   Google Scholar
• Barai SR, Suryawanshi SA, Pandey AK. Responses of parathyroid gland, C cells, and plasma calcium and inorganic phosphate levels in rat to sub-lethal heroin administration. J. Environ. Biol.30(5 Suppl.), 917–922 (2009).
   PubMedGoogle Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J. Intern. Med.260(1), 76–87 (2006).
   PubMed Web of Science ®Google Scholar
• Hoehe M, Duka T. Opiates increase plasma catecholamines in humans. Psychoneuroendocrinology18(2), 141–148 (1993).
   PubMed Web of Science ®Google Scholar
• De Leon-Jones FA, Davis JM, Inwang EE, Dekirmenjian H. Excretion of catecholamine metabolites during methadone maintenance and withdrawal. Arch. Gen. Psychiatry40(8), 841–847 (1983).
   PubMedGoogle Scholar